If approved by the Food and Drug Administration (FDA), this would be the first time MDMA-assisted therapy and psychedelic-assisted therapy would be available through health clinics.
The FDA accepted its new drug application for midomafetamine capsules ("MDMA") used in combination with psychological intervention, which includes psychotherapy (talk therapy) and other supportive services provided by a qualified healthcare provider for individuals with post-traumatic stress disorder (PTSD). The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 11, 2024. If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy, and NovelPath Behavior Wellness is positioning itself to be one of the first qualified healthcare providers facilitating MDMA-assisted therapy, with a focus on serving systems-impacted communities, including BIPOC and Tribal Nations in the greater Seattle area.